InsidersTradesSigma
Follow the GRIFOLS, S.A stock price and the full directors' dealings record of the company, a publicly traded company based in Spain. Shares are listed on the ES market, under the oversight of CNMV. Operating in the Health Care sector, GRIFOLS, S.A has recorded 1 reports. Market capitalisation: €6.5bn. The latest transaction was disclosed on 25 May 2021 (Sale). Among the most active insiders: Victor Grifols Roura. Every trade is accessible without an account.
Analysts rate GRIFOLS, S.A Buy (bullish), based on 8 analysts. Average price target: €21.32.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
GRIFOLS, S.A is a Spanish company specializing in the production of plasma-derived products and intravenous solutions. It is listed on the Spanish stock market, XMAD.